Notice of AGM
(Thomson Reuters ONE) - Summit Corporation plc("Summit" or "the Company")NOTICE OF ANNUAL GENERAL MEETINGOxford, UK, 29 July 2009 - Summit Corporation plc (AIM: SUMM), a UKdrug discovery company, announces that its Annual Report and Accountsfor the year ended 31 January 2009 ('Annual Report') together withthe Notice of Annual General Meeting ('AGM') and Proposed CapitalReorganisation have been posted to shareholders. Copies of theAnnual Report will also be available on the Company's website,www.summitplc.com.The AGM will be held at the Company's registered office, 91 MiltonPark, Abingdon, Oxfordshire, OX14 4RY, on Thursday, 20 August 2009 at10am. - ENDS -For more information, please contact:Summit plcSteven Lee, PhDRichard Pye, PhDTel: +44 (0)1235 443951Panmure GordonAndrew Burnett / Rakesh Sharma (Corporate Finance)Ashton Clanfield (Corporate Broking)Tel: +44 (0)207 459 3600About Summit plcSummit plc is a UK based drug discovery company with a major focus ondeveloping new therapeutics from its iminosugar drug discoveryplatform.Summit believes iminosugars are the key to gaining access to severaldisease mechanisms where classical drugs have had little success, andthus offer a major opportunity for the discovery and development ofnew medicines.Carbohydrates (sugars) play critical roles in maintaining correctfunctioning of many normal processes in healthy individuals anderrors in carbohydrate recognition or modification can lead tomalfunction in cells resulting in disease.Iminosugars have the potential to mimic carbohydrates or to interactwith processes which manipulate carbohydrates to modify activity orto correct aberrant function. Additionally, the structural featuresof iminosugars allow them to have, have important effects wheninteracting with many other unexploited therapeutic targets.Commercially, Summit has a track record of signing programmeagreements and currently has an out-licensed product portfoliocomprising of four drug programmes with BioMarin, Orient Europharma,Evolva and the Lilly TB Drug Discovery Initiative. In the futurethese programmes may generate success based milestone payments androyalties for Summit.In addition, Summit owns Dextra Laboratories, a business unit thatoperates independently to Summit, which offers specialistcarbohydrate chemistry services to third parties on a fee-for-serviceor collaborative basis.The company listed on the alternative investment market (AIM) of theLondon Stock Exchange in October 2004 - symbol: SUMM. Furtherinformation about the company is available at www.summitplc.com.---END OF MESSAGE---This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 29.07.2009 - 17:00 Uhr
Sprache: Deutsch
News-ID 4094
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 422 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Notice of AGM"
steht unter der journalistisch-redaktionellen Verantwortung von
Summit Corporation PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
